OTCMKTS:ECTE

Echo Therapeutics Competitors

$0.02

-0.01 (-32.26 %)

(As of 04/16/2021 12:00 AM ET)

Add

Compare

Today's Range

$0.02

Now: $0.02▼

$0.03

50-Day Range

$0.03

MA: $0.04▼

$0.05

52-Week Range

$0.00

Now: $0.02▼

$0.28

Volume67,111 shs

Average Volume74,197 shs

Market Capitalization$233,730.00

P/E RatioN/A

Dividend YieldN/A

Beta7.09

Echo Therapeutics (OTCMKTS:ECTE) Vs. ARDMQ, IMRSQ, SCIE, ULGX, AKSY, and ESMC

Should you be buying ECTE stock or one of its competitors? Companies in the industry of "electromedical equipment" are considered alternatives and competitors to Echo Therapeutics, including Aradigm (ARDMQ), IMRIS (IMRSQ), SpectraScience (SCIE), Urologix (ULGX), Aksys (AKSY), and Escalon Medical (ESMC).

Echo Therapeutics vs. Aradigm Stock

Aradigm (OTCMKTS:ARDMQ) and Echo Therapeutics (OTCMKTS:ECTE) are both small-cap medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their risk, institutional ownership, earnings, dividends, analyst recommendations, valuation and profitability.

Earnings and Valuation

This table compares Aradigm and Echo Therapeutics' gross revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Aradigm	N/A	N/A	N/A	N/A	N/A
Echo Therapeutics	N/A	N/A	N/A	N/A	N/A

Volatility & Risk

Aradigm has a beta of 2.91, indicating that its share price is 191% more volatile than the S&P 500. Comparatively, Echo Therapeutics has a beta of 7.09, indicating that its share price is 609% more volatile than the S&P 500.

Profitability

This table compares Aradigm and Echo Therapeutics' net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Aradigm	N/A	N/A	N/A
Echo Therapeutics	N/A	N/A	N/A

Analyst Ratings

This is a summary of current ratings and price targets for Aradigm and Echo Therapeutics, as provided by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Aradigm	0	0	0	0	N/A
Echo Therapeutics	0	0	0	0	N/A

Summary

Echo Therapeutics beats Aradigm on 1 of the 1 factors compared between the two stocks.

Echo Therapeutics vs. IMRIS Stock

IMRIS (OTCMKTS:IMRSQ) and Echo Therapeutics (OTCMKTS:ECTE) are both small-cap medical companies, but which is the better investment? We will compare the two businesses based on the strength of their risk, analyst recommendations, profitability, dividends, institutional ownership, earnings and valuation.

Risk & Volatility

IMRIS has a beta of -10.69, meaning that its stock price is 1,169% less volatile than the S&P 500. Comparatively, Echo Therapeutics has a beta of 7.09, meaning that its stock price is 609% more volatile than the S&P 500.

Profitability

This table compares IMRIS and Echo Therapeutics' net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
IMRIS	N/A	N/A	N/A
Echo Therapeutics	N/A	N/A	N/A

Valuation and Earnings

This table compares IMRIS and Echo Therapeutics' revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
IMRIS	N/A	N/A	N/A	N/A	N/A
Echo Therapeutics	N/A	N/A	N/A	N/A	N/A

Analyst Ratings

This is a summary of recent recommendations and price targets for IMRIS and Echo Therapeutics, as provided by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
IMRIS	0	0	0	0	N/A
Echo Therapeutics	0	0	0	0	N/A

Summary

Echo Therapeutics beats IMRIS on 1 of the 1 factors compared between the two stocks.

Echo Therapeutics vs. SpectraScience Stock

Echo Therapeutics (OTCMKTS:ECTE) and SpectraScience (OTCMKTS:SCIE) are both small-cap medical companies, but which is the superior business? We will contrast the two companies based on the strength of their analyst recommendations, profitability, dividends, risk, valuation, earnings and institutional ownership.

Profitability

This table compares Echo Therapeutics and SpectraScience's net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Echo Therapeutics	N/A	N/A	N/A
SpectraScience	N/A	N/A	N/A

Analyst Ratings

This is a breakdown of current recommendations and price targets for Echo Therapeutics and SpectraScience, as provided by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Echo Therapeutics	0	0	0	0	N/A
SpectraScience	0	0	0	0	N/A

Volatility and Risk

Echo Therapeutics has a beta of 7.09, meaning that its share price is 609% more volatile than the S&P 500. Comparatively, SpectraScience has a beta of 0.96, meaning that its share price is 4% less volatile than the S&P 500.

Valuation & Earnings

This table compares Echo Therapeutics and SpectraScience's revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Echo Therapeutics	N/A	N/A	N/A	N/A	N/A
SpectraScience	N/A	N/A	N/A	N/A	N/A

Summary

Echo Therapeutics beats SpectraScience on 1 of the 1 factors compared between the two stocks.

Echo Therapeutics vs. Urologix Stock

Urologix (OTCMKTS:ULGX) and Echo Therapeutics (OTCMKTS:ECTE) are both small-cap medical companies, but which is the better business? We will contrast the two businesses based on the strength of their institutional ownership, valuation, dividends, earnings, analyst recommendations, profitability and risk.

Risk and Volatility

Urologix has a beta of 2.11, meaning that its stock price is 111% more volatile than the S&P 500. Comparatively, Echo Therapeutics has a beta of 7.09, meaning that its stock price is 609% more volatile than the S&P 500.

Analyst Recommendations

This is a summary of recent ratings for Urologix and Echo Therapeutics, as reported by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Urologix	0	0	0	0	N/A
Echo Therapeutics	0	0	0	0	N/A

Valuation and Earnings

This table compares Urologix and Echo Therapeutics' gross revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Urologix	N/A	N/A	N/A	N/A	N/A
Echo Therapeutics	N/A	N/A	N/A	N/A	N/A

Profitability

This table compares Urologix and Echo Therapeutics' net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Urologix	N/A	N/A	N/A
Echo Therapeutics	N/A	N/A	N/A

Summary

Echo Therapeutics beats Urologix on 1 of the 1 factors compared between the two stocks.

Echo Therapeutics vs. Aksys Stock

Aksys (OTCMKTS:AKSY) and Echo Therapeutics (OTCMKTS:ECTE) are both medical companies, but which is the superior stock? We will compare the two companies based on the strength of their dividends, valuation, analyst recommendations, profitability, institutional ownership, earnings and risk.

Profitability

This table compares Aksys and Echo Therapeutics' net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Aksys	N/A	N/A	N/A
Echo Therapeutics	N/A	N/A	N/A

Earnings & Valuation

This table compares Aksys and Echo Therapeutics' revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Aksys	N/A	N/A	N/A	N/A	N/A
Echo Therapeutics	N/A	N/A	N/A	N/A	N/A

Analyst Ratings

This is a summary of current recommendations for Aksys and Echo Therapeutics, as reported by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Aksys	0	0	0	0	N/A
Echo Therapeutics	0	0	0	0	N/A

Volatility & Risk

Aksys has a beta of -6.76, suggesting that its share price is 776% less volatile than the S&P 500. Comparatively, Echo Therapeutics has a beta of 7.09, suggesting that its share price is 609% more volatile than the S&P 500.

Summary

Echo Therapeutics beats Aksys on 1 of the 1 factors compared between the two stocks.

Echo Therapeutics vs. Escalon Medical Stock

Escalon Medical (OTCMKTS:ESMC) and Echo Therapeutics (OTCMKTS:ECTE) are both medical companies, but which is the better business? We will compare the two companies based on the strength of their valuation, earnings, institutional ownership, profitability, dividends, risk and analyst recommendations.

Valuation and Earnings

This table compares Escalon Medical and Echo Therapeutics' gross revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Escalon Medical	$9.40 million	N/A	$-650,000.00	N/A	N/A
Echo Therapeutics	N/A	N/A	N/A	N/A	N/A

Echo Therapeutics has lower revenue, but higher earnings than Escalon Medical.

Volatility & Risk

Escalon Medical has a beta of -0.86, indicating that its stock price is 186% less volatile than the S&P 500. Comparatively, Echo Therapeutics has a beta of 7.09, indicating that its stock price is 609% more volatile than the S&P 500.

Profitability

This table compares Escalon Medical and Echo Therapeutics' net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Escalon Medical	-15.54%	-136.63%	-26.09%
Echo Therapeutics	N/A	N/A	N/A

Analyst Ratings

This is a summary of recent ratings and recommmendations for Escalon Medical and Echo Therapeutics, as reported by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Escalon Medical	0	0	0	0	N/A
Echo Therapeutics	0	0	0	0	N/A

Summary

Echo Therapeutics beats Escalon Medical on 4 of the 5 factors compared between the two stocks.